Corporate Information | |
Chairman’s Statement | 2 |
2021 Interim Results & Business Updates | 3 |
Interim 2021 Financial Results | 8 |
Financial Summary | 10 |
Operations Review | |
Oncology/Immunology |
13 23 |
Use of Non-GAAP Financial Measures and Reconciliation | 25 |
Group Capital Resources | 27 |
Other Information | 32 |
Disclosure of Interests | 35 |
Long Term Incentive Plan | 43 |
Corporate Governance | 45 |
Changes in Information of Directors | 46 |
Interim Unaudited Condensed Consolidated Financial Statements | 47 |
References and Abbreviations | 72 |
Information for Shareholders | |